$9.83+2.6%Nov 13 close
The latest quarter (ended September 30, 2026) is from Sutro Biopharma’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once Sutro Biopharma files it.
Just reported
From Sutro Biopharma, Inc.'s results release of November 12, 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
$9.1M
-6.1% y/y
-7.5% q/q
Guided
—
No guide given
Actual
-$22M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $9.1M | $9.7M | -6.14% |
| Profit | -$31.5M | -$56.9M | +44.62% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Sutro Biopharma, Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Over the past year, we have delivered on our commitment to advance our next-generation ADCs with two programs, STRO-004 and STRO-006, entering the clinic in less than a year, and our dual-payload ADC, STRO-227, expected to follow in early 2027,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from Sutro Biopharma’s earnings press release (an Item 2.02 8-K) filed November 12, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.